ASH 2025 Lymphoma Highlights: Epcoritamab, S1826, Mosunetuzumab & ctDNA | Dr. Sworder ASH 6 Mins Read Published: February 2, 2026Author: Dr. Brian Sworder, MD | City of HopeCategory: ASH 2025 | Lymphoma | Precision Oncology |…
FDA Grants Priority Review of Epcoritamab (EPKINLY): A Significant Step in Lymphoma Treatment [VIDEO EXCLUSIVE] Lymphoma 3 Mins Read The FDA granted Priority Review of the supplemental Biologics License Application (sBLA) for epcoritamab-bysp. This subcutaneously administered T-cell engaging bispecific…
